Updated Trends in Hematopoietic Cell Transplantation in the United States with an Additional Focus on Adolescent and Young Adult Transplantation Activity and Outcomes

• Published in: Transplantation and cellular therapy Vol. 28; no. 7; pp. 409.e1 - 409.e10
• Main Authors: Phelan, Rachel, Chen, Min, Bupp, Caitrin, Bolon, Yung-Tsi, Broglie, Larisa, Brunner-Grady, Janet, Burns, Linda J., Chhabra, Saurabh, Christianson, Debra, Cusatis, Rachel, Devine, Steven M., D'Souza, Anita, Eapen, Mary, Hamadani, Mehdi, Hengen, Mary, Lee, Stephanie J., Moskop, Amy, Page, Kristin M., Pasquini, Marcelo, Pérez, Waleska S., Riches, Marcie, Rizzo, Doug, Saber, Wael, Spellman, Stephen R., Stefanski, Heather E., Steinert, Patricia, Weisdorf, Daniel, Horowitz, Mary, Auletta, Jeffery J., Shaw, Bronwen E., Arora, Mukta
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.07.2022
• Subjects: Activity; Adolescent; Adolescent and young adult; Aged; Child; Hematopoietic cell transplantation; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Peripheral Blood Stem Cell Transplantation; Summary slides; Transplantation Conditioning; Transplantation, Homologous; United States - epidemiology; Young Adult; United States; Adolescent and young adult; Activity; Hematopoietic cell transplantation; Summary slides
• ISSN: 2666-6367; 2666-6375; 2666-6367
• DOI: 10.1016/j.jtct.2022.04.012

•As supportive care, donor selection, and treatment modalities evolve, documenting trends and outcomes of hematopoietic cell transplantation (HCT) is critical.•The expanded use of HCT for older patients is evident in both the autologous and allogeneic settings.•There have been recent increases in haploidentical donor use as well as in studies evaluating the used of mismatched unrelated donors, both of which potentially increase the access to HCT for those with limited traditional donor options.•Recurrence of disease following HCT remains the major cause of death, highlighting the need for improved upfront and maintenance strategies for malignancies.•Comparing the time periods 2000 to 2009 and 2010 to 2019 revealed significant improvement in overall survival across the age spectrum, but the greatest improvement in the adolescent and young adult (AYA) age group. Hematopoietic cell transplantation (HCT) has been successfully used to treat many malignant and nonmalignant conditions. As supportive care, donor selection, and treatment modalities evolve, documenting HCT trends and outcomes is critical. This report from the Center for International Blood and Marrow Transplant Research (CIBMTR) provides an update on current transplantation activity and survival rates in the United States. Additional data on the use and outcomes of HCT in the adolescent and young adult (AYA) population are included. AYA patients more frequently receive peripheral blood stem cell grafts than pediatric patients, which may reflect differences in practice in pediatric versus adult treatment centers. The proportions of donor types also differ those in adult and pediatric populations. Outcomes for patients in the AYA age range are similar to those of pediatric patients for acute myelogenous leukemia but worse for acute lymphoblastic leukemia. Outcomes for both leukemias are better in AYA patients compared with older adults. Comparing the time periods 2000 to 2009 and 2010 to 2019 revealed significant improvement in overall survival across the age spectrum, but the greatest improvement in the AYA age group.